PMC:7104244 / 2335-3849 JSONTXT

{"project":"LitCovid-PubTator","denotations":[{"id":"35","span":{"begin":274,"end":284},"obj":"Species"},{"id":"36","span":{"begin":405,"end":415},"obj":"Species"},{"id":"37","span":{"begin":707,"end":715},"obj":"Species"},{"id":"38","span":{"begin":1129,"end":1134},"obj":"Species"},{"id":"39","span":{"begin":1406,"end":1414},"obj":"Species"},{"id":"40","span":{"begin":17,"end":25},"obj":"Disease"},{"id":"41","span":{"begin":673,"end":698},"obj":"Disease"},{"id":"42","span":{"begin":728,"end":736},"obj":"Disease"},{"id":"43","span":{"begin":1256,"end":1265},"obj":"Disease"}],"attributes":[{"id":"A35","pred":"tao:has_database_id","subj":"35","obj":"Tax:2697049"},{"id":"A36","pred":"tao:has_database_id","subj":"36","obj":"Tax:2697049"},{"id":"A37","pred":"tao:has_database_id","subj":"37","obj":"Tax:9606"},{"id":"A38","pred":"tao:has_database_id","subj":"38","obj":"Tax:9606"},{"id":"A39","pred":"tao:has_database_id","subj":"39","obj":"Tax:9606"},{"id":"A40","pred":"tao:has_database_id","subj":"40","obj":"MESH:C000657245"},{"id":"A41","pred":"tao:has_database_id","subj":"41","obj":"MESH:D012817"},{"id":"A42","pred":"tao:has_database_id","subj":"42","obj":"MESH:C000657245"},{"id":"A43","pred":"tao:has_database_id","subj":"43","obj":"MESH:D007239"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"Given the global COVID-19 outbreak, we, as an international group of experts in faecal microbiota transplantation and stool banking, believe that recommendations to update (at least temporarily) the screening of stool donors are urgently needed, as the risk of transmitting SARS-CoV-2 by faecal microbiota transplantation might be higher than that in other tissue transplants. Evidence has shown that the SARS-CoV-2 can be found in faeces, and that stool samples can remain positive for the virus even when it is no longer detectable in the respiratory tract, suggesting the possibility of a faecal–oral route of transmission.9 This concept is supported by the presence of gastrointestinal symptoms in some patients affected by COVID-19.10 Another relevant issue is that faecal microbiota transplantation is not classified in the same way worldwide, as some countries regulate these transplants as a drug (eg, the USA, the UK, and France), some as a tissue (eg, Italy), and others do not provide specific regulation (eg, Australia).8 This discrepancy results in a confusing scenario, in which some countries will apply rules for human cells, tissues, or cellular or tissue-based products, and others will not, potentially contributing to the spread of the infection. A more alarming issue is represented by the uncontrolled practice of homemade faecal microbiota transplantation, which is widespread among patients who want to try this treatment for indications outside of clinical guidelines or clinical trials.11"}

{"project":"LitCovid-PMC-OGER-BB","denotations":[{"id":"T69","span":{"begin":17,"end":25},"obj":"SP_7"},{"id":"T68","span":{"begin":118,"end":123},"obj":"UBERON:0001988"},{"id":"T67","span":{"begin":212,"end":217},"obj":"UBERON:0001988"},{"id":"T66","span":{"begin":274,"end":284},"obj":"SP_7"},{"id":"T65","span":{"begin":357,"end":363},"obj":"UBERON:0000479"},{"id":"T64","span":{"begin":405,"end":415},"obj":"SP_7"},{"id":"T63","span":{"begin":432,"end":438},"obj":"UBERON:0001988"},{"id":"T62","span":{"begin":449,"end":454},"obj":"UBERON:0001988"},{"id":"T61","span":{"begin":491,"end":496},"obj":"NCBITaxon:10239"},{"id":"T60","span":{"begin":541,"end":558},"obj":"UBERON:0000065"},{"id":"T59","span":{"begin":599,"end":603},"obj":"UBERON:0000165"},{"id":"T58","span":{"begin":673,"end":689},"obj":"UBERON:0001555"},{"id":"T57","span":{"begin":728,"end":736},"obj":"SP_7"},{"id":"T56","span":{"begin":868,"end":876},"obj":"GO:0065007"},{"id":"T55","span":{"begin":900,"end":904},"obj":"CHEBI:23888;CHEBI:23888"},{"id":"T54","span":{"begin":950,"end":956},"obj":"UBERON:0000479"},{"id":"T53","span":{"begin":1005,"end":1015},"obj":"GO:0065007"},{"id":"T52","span":{"begin":1129,"end":1134},"obj":"SP_6;NCBITaxon:9606"},{"id":"T51","span":{"begin":1142,"end":1149},"obj":"UBERON:0000479"},{"id":"T50","span":{"begin":1166,"end":1172},"obj":"UBERON:0000479"}],"text":"Given the global COVID-19 outbreak, we, as an international group of experts in faecal microbiota transplantation and stool banking, believe that recommendations to update (at least temporarily) the screening of stool donors are urgently needed, as the risk of transmitting SARS-CoV-2 by faecal microbiota transplantation might be higher than that in other tissue transplants. Evidence has shown that the SARS-CoV-2 can be found in faeces, and that stool samples can remain positive for the virus even when it is no longer detectable in the respiratory tract, suggesting the possibility of a faecal–oral route of transmission.9 This concept is supported by the presence of gastrointestinal symptoms in some patients affected by COVID-19.10 Another relevant issue is that faecal microbiota transplantation is not classified in the same way worldwide, as some countries regulate these transplants as a drug (eg, the USA, the UK, and France), some as a tissue (eg, Italy), and others do not provide specific regulation (eg, Australia).8 This discrepancy results in a confusing scenario, in which some countries will apply rules for human cells, tissues, or cellular or tissue-based products, and others will not, potentially contributing to the spread of the infection. A more alarming issue is represented by the uncontrolled practice of homemade faecal microbiota transplantation, which is widespread among patients who want to try this treatment for indications outside of clinical guidelines or clinical trials.11"}

{"project":"LitCovid-PD-FMA-UBERON","denotations":[{"id":"T14","span":{"begin":118,"end":123},"obj":"Body_part"},{"id":"T15","span":{"begin":212,"end":217},"obj":"Body_part"},{"id":"T16","span":{"begin":357,"end":363},"obj":"Body_part"},{"id":"T17","span":{"begin":432,"end":438},"obj":"Body_part"},{"id":"T18","span":{"begin":449,"end":454},"obj":"Body_part"},{"id":"T19","span":{"begin":541,"end":558},"obj":"Body_part"},{"id":"T20","span":{"begin":950,"end":956},"obj":"Body_part"},{"id":"T21","span":{"begin":1135,"end":1140},"obj":"Body_part"},{"id":"T22","span":{"begin":1142,"end":1149},"obj":"Body_part"},{"id":"T23","span":{"begin":1166,"end":1172},"obj":"Body_part"}],"attributes":[{"id":"A14","pred":"fma_id","subj":"T14","obj":"http://purl.org/sig/ont/fma/fma64183"},{"id":"A15","pred":"fma_id","subj":"T15","obj":"http://purl.org/sig/ont/fma/fma64183"},{"id":"A16","pred":"fma_id","subj":"T16","obj":"http://purl.org/sig/ont/fma/fma9637"},{"id":"A17","pred":"fma_id","subj":"T17","obj":"http://purl.org/sig/ont/fma/fma64183"},{"id":"A18","pred":"fma_id","subj":"T18","obj":"http://purl.org/sig/ont/fma/fma64183"},{"id":"A19","pred":"fma_id","subj":"T19","obj":"http://purl.org/sig/ont/fma/fma265130"},{"id":"A20","pred":"fma_id","subj":"T20","obj":"http://purl.org/sig/ont/fma/fma9637"},{"id":"A21","pred":"fma_id","subj":"T21","obj":"http://purl.org/sig/ont/fma/fma68646"},{"id":"A22","pred":"fma_id","subj":"T22","obj":"http://purl.org/sig/ont/fma/fma9637"},{"id":"A23","pred":"fma_id","subj":"T23","obj":"http://purl.org/sig/ont/fma/fma9637"}],"text":"Given the global COVID-19 outbreak, we, as an international group of experts in faecal microbiota transplantation and stool banking, believe that recommendations to update (at least temporarily) the screening of stool donors are urgently needed, as the risk of transmitting SARS-CoV-2 by faecal microbiota transplantation might be higher than that in other tissue transplants. Evidence has shown that the SARS-CoV-2 can be found in faeces, and that stool samples can remain positive for the virus even when it is no longer detectable in the respiratory tract, suggesting the possibility of a faecal–oral route of transmission.9 This concept is supported by the presence of gastrointestinal symptoms in some patients affected by COVID-19.10 Another relevant issue is that faecal microbiota transplantation is not classified in the same way worldwide, as some countries regulate these transplants as a drug (eg, the USA, the UK, and France), some as a tissue (eg, Italy), and others do not provide specific regulation (eg, Australia).8 This discrepancy results in a confusing scenario, in which some countries will apply rules for human cells, tissues, or cellular or tissue-based products, and others will not, potentially contributing to the spread of the infection. A more alarming issue is represented by the uncontrolled practice of homemade faecal microbiota transplantation, which is widespread among patients who want to try this treatment for indications outside of clinical guidelines or clinical trials.11"}

{"project":"LitCovid-PD-UBERON","denotations":[{"id":"T8","span":{"begin":118,"end":123},"obj":"Body_part"},{"id":"T9","span":{"begin":212,"end":217},"obj":"Body_part"},{"id":"T10","span":{"begin":357,"end":363},"obj":"Body_part"},{"id":"T11","span":{"begin":432,"end":438},"obj":"Body_part"},{"id":"T12","span":{"begin":449,"end":454},"obj":"Body_part"},{"id":"T13","span":{"begin":541,"end":558},"obj":"Body_part"},{"id":"T14","span":{"begin":950,"end":956},"obj":"Body_part"},{"id":"T15","span":{"begin":1166,"end":1172},"obj":"Body_part"}],"attributes":[{"id":"A8","pred":"uberon_id","subj":"T8","obj":"http://purl.obolibrary.org/obo/UBERON_0001988"},{"id":"A9","pred":"uberon_id","subj":"T9","obj":"http://purl.obolibrary.org/obo/UBERON_0001988"},{"id":"A10","pred":"uberon_id","subj":"T10","obj":"http://purl.obolibrary.org/obo/UBERON_0000479"},{"id":"A11","pred":"uberon_id","subj":"T11","obj":"http://purl.obolibrary.org/obo/UBERON_0001988"},{"id":"A12","pred":"uberon_id","subj":"T12","obj":"http://purl.obolibrary.org/obo/UBERON_0001988"},{"id":"A13","pred":"uberon_id","subj":"T13","obj":"http://purl.obolibrary.org/obo/UBERON_0000065"},{"id":"A14","pred":"uberon_id","subj":"T14","obj":"http://purl.obolibrary.org/obo/UBERON_0000479"},{"id":"A15","pred":"uberon_id","subj":"T15","obj":"http://purl.obolibrary.org/obo/UBERON_0000479"}],"text":"Given the global COVID-19 outbreak, we, as an international group of experts in faecal microbiota transplantation and stool banking, believe that recommendations to update (at least temporarily) the screening of stool donors are urgently needed, as the risk of transmitting SARS-CoV-2 by faecal microbiota transplantation might be higher than that in other tissue transplants. Evidence has shown that the SARS-CoV-2 can be found in faeces, and that stool samples can remain positive for the virus even when it is no longer detectable in the respiratory tract, suggesting the possibility of a faecal–oral route of transmission.9 This concept is supported by the presence of gastrointestinal symptoms in some patients affected by COVID-19.10 Another relevant issue is that faecal microbiota transplantation is not classified in the same way worldwide, as some countries regulate these transplants as a drug (eg, the USA, the UK, and France), some as a tissue (eg, Italy), and others do not provide specific regulation (eg, Australia).8 This discrepancy results in a confusing scenario, in which some countries will apply rules for human cells, tissues, or cellular or tissue-based products, and others will not, potentially contributing to the spread of the infection. A more alarming issue is represented by the uncontrolled practice of homemade faecal microbiota transplantation, which is widespread among patients who want to try this treatment for indications outside of clinical guidelines or clinical trials.11"}

{"project":"LitCovid-PD-MONDO","denotations":[{"id":"T12","span":{"begin":17,"end":25},"obj":"Disease"},{"id":"T13","span":{"begin":274,"end":282},"obj":"Disease"},{"id":"T14","span":{"begin":405,"end":413},"obj":"Disease"},{"id":"T15","span":{"begin":1256,"end":1265},"obj":"Disease"}],"attributes":[{"id":"A12","pred":"mondo_id","subj":"T12","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A13","pred":"mondo_id","subj":"T13","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"},{"id":"A14","pred":"mondo_id","subj":"T14","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"},{"id":"A15","pred":"mondo_id","subj":"T15","obj":"http://purl.obolibrary.org/obo/MONDO_0005550"}],"text":"Given the global COVID-19 outbreak, we, as an international group of experts in faecal microbiota transplantation and stool banking, believe that recommendations to update (at least temporarily) the screening of stool donors are urgently needed, as the risk of transmitting SARS-CoV-2 by faecal microbiota transplantation might be higher than that in other tissue transplants. Evidence has shown that the SARS-CoV-2 can be found in faeces, and that stool samples can remain positive for the virus even when it is no longer detectable in the respiratory tract, suggesting the possibility of a faecal–oral route of transmission.9 This concept is supported by the presence of gastrointestinal symptoms in some patients affected by COVID-19.10 Another relevant issue is that faecal microbiota transplantation is not classified in the same way worldwide, as some countries regulate these transplants as a drug (eg, the USA, the UK, and France), some as a tissue (eg, Italy), and others do not provide specific regulation (eg, Australia).8 This discrepancy results in a confusing scenario, in which some countries will apply rules for human cells, tissues, or cellular or tissue-based products, and others will not, potentially contributing to the spread of the infection. A more alarming issue is represented by the uncontrolled practice of homemade faecal microbiota transplantation, which is widespread among patients who want to try this treatment for indications outside of clinical guidelines or clinical trials.11"}

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T25","span":{"begin":386,"end":389},"obj":"http://purl.obolibrary.org/obo/CLO_0051582"},{"id":"T26","span":{"begin":491,"end":496},"obj":"http://purl.obolibrary.org/obo/NCBITaxon_10239"},{"id":"T27","span":{"begin":590,"end":591},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T28","span":{"begin":898,"end":899},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T29","span":{"begin":948,"end":949},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T30","span":{"begin":1062,"end":1063},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T31","span":{"begin":1129,"end":1140},"obj":"http://purl.obolibrary.org/obo/CLO_0053065"},{"id":"T32","span":{"begin":1267,"end":1268},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T33","span":{"begin":1512,"end":1514},"obj":"http://purl.obolibrary.org/obo/CLO_0053733"}],"text":"Given the global COVID-19 outbreak, we, as an international group of experts in faecal microbiota transplantation and stool banking, believe that recommendations to update (at least temporarily) the screening of stool donors are urgently needed, as the risk of transmitting SARS-CoV-2 by faecal microbiota transplantation might be higher than that in other tissue transplants. Evidence has shown that the SARS-CoV-2 can be found in faeces, and that stool samples can remain positive for the virus even when it is no longer detectable in the respiratory tract, suggesting the possibility of a faecal–oral route of transmission.9 This concept is supported by the presence of gastrointestinal symptoms in some patients affected by COVID-19.10 Another relevant issue is that faecal microbiota transplantation is not classified in the same way worldwide, as some countries regulate these transplants as a drug (eg, the USA, the UK, and France), some as a tissue (eg, Italy), and others do not provide specific regulation (eg, Australia).8 This discrepancy results in a confusing scenario, in which some countries will apply rules for human cells, tissues, or cellular or tissue-based products, and others will not, potentially contributing to the spread of the infection. A more alarming issue is represented by the uncontrolled practice of homemade faecal microbiota transplantation, which is widespread among patients who want to try this treatment for indications outside of clinical guidelines or clinical trials.11"}

{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T4","span":{"begin":60,"end":65},"obj":"Chemical"},{"id":"T5","span":{"begin":900,"end":904},"obj":"Chemical"}],"attributes":[{"id":"A4","pred":"chebi_id","subj":"T4","obj":"http://purl.obolibrary.org/obo/CHEBI_24433"},{"id":"A5","pred":"chebi_id","subj":"T5","obj":"http://purl.obolibrary.org/obo/CHEBI_23888"}],"text":"Given the global COVID-19 outbreak, we, as an international group of experts in faecal microbiota transplantation and stool banking, believe that recommendations to update (at least temporarily) the screening of stool donors are urgently needed, as the risk of transmitting SARS-CoV-2 by faecal microbiota transplantation might be higher than that in other tissue transplants. Evidence has shown that the SARS-CoV-2 can be found in faeces, and that stool samples can remain positive for the virus even when it is no longer detectable in the respiratory tract, suggesting the possibility of a faecal–oral route of transmission.9 This concept is supported by the presence of gastrointestinal symptoms in some patients affected by COVID-19.10 Another relevant issue is that faecal microbiota transplantation is not classified in the same way worldwide, as some countries regulate these transplants as a drug (eg, the USA, the UK, and France), some as a tissue (eg, Italy), and others do not provide specific regulation (eg, Australia).8 This discrepancy results in a confusing scenario, in which some countries will apply rules for human cells, tissues, or cellular or tissue-based products, and others will not, potentially contributing to the spread of the infection. A more alarming issue is represented by the uncontrolled practice of homemade faecal microbiota transplantation, which is widespread among patients who want to try this treatment for indications outside of clinical guidelines or clinical trials.11"}

{"project":"LitCovid-PD-GO-BP","denotations":[{"id":"T1","span":{"begin":1005,"end":1015},"obj":"http://purl.obolibrary.org/obo/GO_0065007"}],"text":"Given the global COVID-19 outbreak, we, as an international group of experts in faecal microbiota transplantation and stool banking, believe that recommendations to update (at least temporarily) the screening of stool donors are urgently needed, as the risk of transmitting SARS-CoV-2 by faecal microbiota transplantation might be higher than that in other tissue transplants. Evidence has shown that the SARS-CoV-2 can be found in faeces, and that stool samples can remain positive for the virus even when it is no longer detectable in the respiratory tract, suggesting the possibility of a faecal–oral route of transmission.9 This concept is supported by the presence of gastrointestinal symptoms in some patients affected by COVID-19.10 Another relevant issue is that faecal microbiota transplantation is not classified in the same way worldwide, as some countries regulate these transplants as a drug (eg, the USA, the UK, and France), some as a tissue (eg, Italy), and others do not provide specific regulation (eg, Australia).8 This discrepancy results in a confusing scenario, in which some countries will apply rules for human cells, tissues, or cellular or tissue-based products, and others will not, potentially contributing to the spread of the infection. A more alarming issue is represented by the uncontrolled practice of homemade faecal microbiota transplantation, which is widespread among patients who want to try this treatment for indications outside of clinical guidelines or clinical trials.11"}

{"project":"LitCovid-sentences","denotations":[{"id":"T8","span":{"begin":0,"end":376},"obj":"Sentence"},{"id":"T9","span":{"begin":377,"end":1266},"obj":"Sentence"},{"id":"T10","span":{"begin":1267,"end":1514},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"Given the global COVID-19 outbreak, we, as an international group of experts in faecal microbiota transplantation and stool banking, believe that recommendations to update (at least temporarily) the screening of stool donors are urgently needed, as the risk of transmitting SARS-CoV-2 by faecal microbiota transplantation might be higher than that in other tissue transplants. Evidence has shown that the SARS-CoV-2 can be found in faeces, and that stool samples can remain positive for the virus even when it is no longer detectable in the respiratory tract, suggesting the possibility of a faecal–oral route of transmission.9 This concept is supported by the presence of gastrointestinal symptoms in some patients affected by COVID-19.10 Another relevant issue is that faecal microbiota transplantation is not classified in the same way worldwide, as some countries regulate these transplants as a drug (eg, the USA, the UK, and France), some as a tissue (eg, Italy), and others do not provide specific regulation (eg, Australia).8 This discrepancy results in a confusing scenario, in which some countries will apply rules for human cells, tissues, or cellular or tissue-based products, and others will not, potentially contributing to the spread of the infection. A more alarming issue is represented by the uncontrolled practice of homemade faecal microbiota transplantation, which is widespread among patients who want to try this treatment for indications outside of clinical guidelines or clinical trials.11"}